reported on the 30th that it applied for a U.S. patent for COVID-19 treatment,
which is based on the company-developed immune-checkpoint inhibitor “STT-003”
Currently geared for clinical trials, the
‘STT-003’ antibody can have multiple applicability - as an anticancer
immunotherapy as well as treatment for viruses such as COVID-19.
It is known that immune-checkpoint
inhibitors such as ‘STT-003’ antibodies facilitate functions of immune cells in
the chronic inflammation state and induce the secretion of cytokines that
stimulate immune cells such as interleukin-2 (IL-2) and Interferon-γ, providing
rationale for use of these agents as antiviral treatments.
In connection with the development of
COVID-19 treatment, STCube entered into a contract with Nexelis, a contract
research organization (CRO) based in Canada, on the 23rd and is currently conducting
preclinical research on the ‘STT-003’ antibody.
In the preclinical research, the company
plans to assess the antiviral efficacy asserted through cytokine secretion and immue
regulation using lymphocytic choriomeningitis virus (LCMV) infection model and
humanized mouse model.
The ‘STT-003’ antibody is expected to be
highly effective as an antiviral therapeutic agent particularly in elderly
patients and those with impaired immune functions due to an underlying problem.
An official of STCube stated: “In order to
promptly develop antibody medicines against highly infectious and lethal viruses
such as COVID-19, we applied for the U.S. patent. As soon as the antiviral
effect is verified through preclinical research, we will initiate clinical
trials on COVID-19." <End>